drugset
Drugs / rhPRG4
last change Sep 2026 re-read 3 minutes ago

rhPRG4

also known as RECOMBINANT HUMAN PROTEOGLYCAN 4

Protein / enzyme biologic

Developed for
chronic graft versus host disease · graft versus host disease · Sjogren syndrome
Investigated by
Lubris Bio Pty Ltd · Lubris, LLC · Sydney Eye Hospital

Trials 3

today NCT07118254 · Ph 2 NCT06495307 · Ph 1/2 NCT06520202 · Ph 1/2
20252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/22 trials
Phase 1/2 NCT06495307 Feb → Mar 2025 chronic graft versus host disease Lubris Bio Pty Ltd Terminated No outcome recorded
Phase 1/2 NCT06520202 Nov 2024 Sjogren syndrome Lubris Bio Pty Ltd Terminated No outcome recorded
Phase 21 trial
Phase 2 NCT07118254 Sep 2025 → Sep 2026 overdue graft versus host disease Lubris Bio Pty Ltd Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as RHPRG4 “RHPRG4 (450 µG/ML) RECOMBINANT HUMAN PROTEOGLYCAN 4” NCT06495307 ↗
3

NCT06520202 ↗

NCT07118254 ↗

NCT06495307 ↗
Known as RECOMBINANT HUMAN PROTEOGLYCAN 4 “RHPRG4 (450 µG/ML) RECOMBINANT HUMAN PROTEOGLYCAN 4” NCT06495307 ↗
1

“RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4)” NCT07118254 ↗
Modality Protein / enzyme biologic “450 µG/ML) RECOMBINANT HUMAN PROTEOGLYCAN 4” NCT06495307 ↗
Route Topical “for topical administration” NCT06495307 ↗